Research programme: antbody-drug conjugates - LegoChem/Nordic Nanovector

Drug Profile

Research programme: antbody-drug conjugates - LegoChem/Nordic Nanovector

Alternative Names: anti-CD37 ADC - Nordic Nanovector; anti-CD37 antibody - Nordic Nanovector; LCB14 15XX - LegoChem/Nordic Nanovector

Latest Information Update: 24 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LegoChem Biosciences; Nordic Nanovector
  • Developer Nordic Nanovector
  • Class Antibodies; Antineoplastics; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Leukaemia

Most Recent Events

  • 10 Oct 2016 Nordic NanoVector and LegoChem Biosciences enter a research collaboration for antibody-drug conjugates
  • 10 Oct 2016 Early research in Leukaemia in Norway (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top